GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated May 1, 2026

Quick Answer

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD.


Introduction:

Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue these therapies within 1–2 years because of cost, adverse effects, or limited access, often leading to rapid weight regain.

Why was this study needed?

  • Weight regain commonly occurs after GLP-1 receptor agonist discontinuation.
  • Long-term maintenance strategies after stopping GLP-1 therapy are lacking.
  • A non-pharmacological approach may help sustain metabolic benefits.
  • The duodenum plays a central role in glucose metabolism and insulin resistance.
  • Endoscopic metabolic therapies are emerging as less invasive alternatives to surgery.

Results:

  • A single session of Duodenal Mucosal Resurfacing (DMR) helped maintain weight loss and metabolic improvements after GLP-1 discontinuation.
  • DMR appears to function as an "off-ramp" therapy, reducing early rebound weight gain after stopping GLP-1 treatment.
  • These findings support the concept that combining pharmacological and endoscopic metabolic therapies may provide more durable long-term outcomes than either approach alone.

Clinical Impact:

DMR is a minimally invasive endoscopic procedure that uses hydrothermal ablation to regenerate the duodenal mucosa, targeting abnormal metabolic signaling rather than simply reducing caloric intake. If confirmed in larger studies, DMR may become an attractive strategy for maintaining weight loss after GLP-1 withdrawal and reducing lifelong dependence on medication.

Bottom Line:

The future of obesity treatment may not be lifelong medication alone. Combining GLP-1 therapy for weight loss induction with Duodenal Mucosal Resurfacing for long-term maintenance could represent a new paradigm in metabolic disease management.

Related Q&A

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may...

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a...

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding...

Remimazolam Improves Sedation Safety During ERCP : GIE | Jun 2026

Introduction: Deep sedation is essential for successful endoscopic retrograde cholangiopancreatography (ERCP), a technically complex procedure frequently performed in elderly patients and those with significant comorbidities. Propofol remains the most commonly used sedative agent because of...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer